Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprint requires authorization.
PharmaCircleMonitoring shows: Recently, Anlong Biomedical, from Beijing, announced the completionNearly 100 Million B+ Round FinancingThis round of financing was invested by the Beijing Medical and Health Industry Investment Fund and the Beijing Shunyi Airport Economic Zone Industry Fund, with funding from both municipal and district levels.At the same time, the company also collaborates with aU.S. Nasdaq-listed pharmaceutical company reaches international strategic cooperation agreement in the small nucleic acid drug field, with a cooperation scale reaching hundreds of millions of dollars.After years of investment, the company has strategically expanded in two major technological platforms: AAV for gene therapy and siRNA for small nucleic acid drugs. Collaborations with multiple listed companies in China have not only honed its R&D and clinical teams but also validated the company’s technical capabilities in liver-targeted delivery systems. Meanwhile, partnerships with overseas enterprises have further demonstrated its extrahepatic targeting delivery capabilities, providing strong support for proprietary products to enter international markets such as Europe and the U.S. While expanding into global markets, Anlong has retained the rights to the Greater China market, ensuring it can continue to provide high-value innovative therapies to Chinese patients in the future.References:
PharmaCircle Data;
MoEntropy Pharma pharma.bcpmdata.com (formerly Yaorong Cloud Data); etc.
StreetInsider；
Etc.
